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Abstract Current treatment modalities can cure up to 70–
80 % of patients with classical Hodgkin lymphoma. Approx-
imately, 20–30% of patients require further treatment options.
Brentuximab vedotin has been approved for the treatment of
relapsed and refractory Hodgkin lymphoma. In the present
study, we report the experience with brentuximab vedotin as
single agent in 58 patients with relapsed or refractory Hodgkin
lymphoma. The objective response rate was 63.5 % with 13
complete responders (26.5 %) among 49 patients evaluated at
the early phase of treatment (2–5 cycles). Upon treatment
prolongation (≥6 cycles), 37 patients achieved a final objec-
tive response rate of 32.4 % with 21.6 % of complete and
10.8 % of partial response. Overall survival at 12 months was
70.6 %, and progression-free survival at 12 months was
32.8 %. Median overall survival could not be reached and
median progression-free survival was 7 months. While the
median duration of response was 9 months in the whole
cohort, it was 11.5 months in the complete responders. Com-
plete response rates in patients treated with >3 chemotherapy
regimens before brentuximab vedotin were significantly lower
(p=0.016). Fourteen patients were subsequently transplanted.
In conclusion, brentuximab vedotin provided a bridge to
transplantation in approximately one quarter of the patients.
The declining response rates during the course of treatment
suggest that transplantation should be implemented early dur-
ing brentuximab vedotin treatment.
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Introduction
Classical Hodgkin lymphoma (cHL) is one of the most cur-
able cancers. However, approximately a third of patients will
relapse after first-line therapy and 15 % will fail both first and
second line therapies, and therapeutic options are still quite
limited in these patients [1]. Brentuximab vedotin (BV) is a
novel antibody-drug conjugate composed of a CD30-directed
recombinant chimeric immunoglobulin G1 covalently linked
to a synthetic antitubulin chemotherapeutic agent
monomethyl auristatin E. BV showed an impressive activity
against relapsed/refractory cHL [2].
We would like to provide more information on the efficacy
and safety of BV and contribute to the determination of the
best role and timing of BV treatment in the current study.
Design and methods
BV is approved for the treatment of cHL after failure of
autologous transplantation or after failure of at least two prior
multi-agent chemotherapy regimens in patients that are not
candidates for transplantation. Eleven Turkish institutions
participated in this multicenter, retrospective study. Eligible
patients were required to be treated with at least two courses of
BV and to have available clinical documentation and staging
investigations. Inclusion of the patients with organ dysfunc-
tion was based on the decision of the attending physician.
All patients underwent baseline assessments including
physical examination, routine laboratory tests, and radiologi-
cal examinations [computed tomography (CT), positron emis-
sion tomography (PET/CT)] prior to the treatment. Patients
were included without any limitations regarding performance
status and organ function. All of the patients provided written
informed consent.
BV is imported via the named-patient-program. BV was
given at a dose of 1.8 mg/kg intravenous infusion over 30 min
every 3 weeks in an outpatient setting. Since the drug is
received institutionally, the relative dose intensity was calcu-
lated as total chemotherapy dose delivered/total chemotherapy
duration [3].
The primary endpoint of the study was the objective re-
sponse rate (ORR); secondary endpoints were safety, overall
survival (OS), and progression-free survival (PFS). Response
was assessed by PET/CT or CT early during disease course
after 2–5 cycles [4] and after ≥6 cycles using the international
working group revised response criteria [5].
Safety and tolerability were assessed before each BV cycle
according to National Cancer Institute Common Terminology
Criteria for Adverse Events Version 4.0. For grade 3 toxicity,
dose reduction of BV to 1.2 mg/kg was recommended.
OS was defined as the time from the initiation of BV to
death of any cause. PFS was the time from treatment initiation
to progression, relapse, or death of any cause [5]. Primary
refractory disease was defined as no complete remission or
relapse within 3 months of first line therapy [6]. Both OS and
PFS were censored at the date of last information. Median
duration of response, PFS, and OS rates along with two-sided
95 % confidence interval (CI) was estimated using the
Kaplan-Meier method. Survival functions were compared
using log-rank test. Analysis of the data was carried out using
STATA 11.1 SE software.
Results
From March 2011 to July 2013, 58 patients in eleven Turkish
centers were treated with BV within the named patient pro-
gram. Outcomes and safety/toxicity data of 58 patients with
relapsed or refractory cHL were analyzed in this study, aiming
to evaluate the efficacy and safety of BV.
Demographics and disease characteristics of the patients
are summarized in Table 1. The median age at diagnosis was
26 years, and 64 % were males. Nodular sclerosis was the
most frequent (79 %) histologic subtype, half of the patients
(49 %) had primary refractory disease, and 72 % were refrac-
tory to the last treatment given before BV. Most of the patients
(77.5 %) had advanced stage disease and approximately half
of them (47 %) had B-symptoms.
A median of 7 (range, 2–18) courses of BV were given as a
single agent (Fig. 1) and relative dose intensity was calculated
as 81.6 %. The results of post-BV assessments are shown in
Fig. 2. PET/CT was performed in 36 patients and 13 were
assessed with CT early during treatment course. Thirty-one
patients underwent PET/CT and 6 were evaluated with CT
scan after ≥6 cycles of BV.
Early assessment after 2–5 cycles of BV
After 2–5 cycles of BV, an objective response rate (ORR) of
63.5 % (n=31) with 26.5 % (n=13) CR was achieved.
In the subgroup of patients with an objective response, the
median PFS duration was 9 months and PFS at 12months was
44.34 % (95 % CI, 24.6 to 62.5 %). In the remaining 18
patients without an objective response, PFS was significantly
lower (p<0.001) with a median PFS of 3 months. OS at
12 months was 80.5 % (95 % CI, 59.0 to 91.5 %) and
57.9 % (95 % CI, 28.6 to 78.8 %) in patients with or without
objective response, respectively. The median OS has not been
reached in either group.
Among the 13 patients who achieved CR at the early
evaluation after 2–5 treatment cycles, the frontline treatment
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regimen was ABVD (adriamycin + bleomycin + vinblastine +
dacarbazine) and the median number of BV courses was nine.
Other characteristics of these patients are given in Table 2. Of
these 13 patients, one died due to infection; five underwent
transplantation (three allogeneic, one haploidentical, and one
autologous) after BVwith a follow-up time of 1month for two
patients; 7, 8, and 12 months for three patients after transplan-
tation; four could not find a matched donor and proceed to
transplantation; one refused transplantation although there
was a matched sibling donor; and one was preparing for
allogeneic transplantation at the time of statistical analysis;
one patient was not a transplant candidate, because allogeneic
transplantation had been already performed.
Five patients were referred to transplantation before 6 cy-
cles of therapy. Three of them underwent allogeneic and one
of them autologous stem cell transplantation. The fifth patient
had not been transplanted yet at the time of statistical analysis.
Twenty-one patients did not undergo a later assessment of
response after ≥6 cycles of treatment. Of these, 11 had disease
progression during early treatment course and discontinued
therapy, one died because of infection and two were awaiting
response evaluation at the time of statistical analysis. Re-
sponse assessment was omitted in two patients after achieving
complete response (CR) during early response evaluation
since these patients did not have any detectable clinical evi-
dence of disease and disease-related symptoms. They were
Table 1 Patient demographics
and disease characteristics
(N=58)
ABVD adriamycin + bleomycin +
vinblastine + dacarbazine, ECOG
Eastern Cooperative Oncology
Group
a Two patients did not have sys-
temic symptom evaluation results
b Nine patients (15 %) had not
undergone stem cell transplanta-
tion previously because of pro-
gressive disease (PD) in seven,
poor mobilization in one, and de-
cision of the attending physician
in another
Median age at diagnosis, years (range) 26 (13–62)
Sex, male/female, n/n 37/21
n (%)
Systemic symptoms at diagnosisa 46 (82)
Histological subtype Nodular sclerosis 46 (79)
Mixed cellularity 6 (10)
Lymphocyte rich 1 (2)
Not determined 5 (9)
Frontline Hodgkin lymphoma regimen ABVD 57 (98)
Prior radiation therapy 45 (77.5)
Prior transplantation (N=49)b autologous 39 (79.6)
allogeneic 1 (2.05)
autologous + allogeneic 8 (16.3)
autologous + haploidentical allogeneic 1 (2.05)
Median prior chemotherapy regimens 4 (2–7)
Primary refractory disease to frontline therapy 28 (49)
Refractoriness to most recent therapy 42/58 (72)
Disease status at the initiation of brentuximab vedotin Stage ΙΙΙ/ΙV 45 (77.5)
B-symptoms 27 (47)
Performance status ECOG score 0 14 (24)
ECOG score 1 32 (55)
ECOG score 2 12 (21)
Fig 1 Number of brentuximab
vedotin course
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treated with 18 courses of BV but could not proceed with
transplantation (one patient had no donor and the other had
autologous and allogeneic transplantation before BV).
Later assessment (after ≥6 cycles of BV)
Nine patients were not evaluated (NE) early during treatment
course based on the attending physician’s decisions (three
achieved CR, two achieved partial remission (PR), and four
were found to have PD), but evaluated after ≥6 cycles.
Response assessment after ≥6 cycles was performed with
PET/CT in 31 of 37 patients and CT in 6 patients and
showed an ORR of 32.4 % (n=12) with CR in 8 patients
(21.6 %). PFS at 12 months was 32.8 % (95 % CI, 19.7 to
46.6 %) and the median PFS duration was 7 months (95 %
CI, 4.8 to 11.3 %) (Fig. 3a). Fourty-four patients were alive
at the time of data analysis. OS at 12 months was 70.6 %
(95 % CI, 54.4 to 81.9 %) and the median OS has not been
reached yet (Fig. 3b).
Fig 2 Results of post-BV
assessments
Table 2 Characteristics of 13 patients who achieved complete remission
at early evaluation, after 2–5 cycles of brentuximab vedotin
Median age at diagnosis, years (range) 25 (16–53)
Sex, male/female, n/n 9/4
Prior radiation therapy, n (%) 11 (85)
Prior transplantation, n (%) autologous stem cell 9 (69)
autologous + allogeneic 1 (7.7)
Number of previous chemotherapy regimens, median (range) 4 (2–6)
Refractory to frontline therapy, n (%) 3 (23)
Refractory to most recent therapy, n (%) 8 (61.5)
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Twelve patients had been treated with three or less previous
chemotherapy regimens before BV and half of the patients
achieved CR. CR rates in patients treated with >3 chemother-
apy regimens before BV were significantly lower (15 %) than
CR rates in patients with fewer prior therapies (p=0.016).
Fourteen patients proceeded to transplantation (7 allogene-
ic, 5 haploidentical, and 2 autologous transplantation). Among
these, 5 patients (36 %) entered transplantation in CR, while 3
(21 %) with stable disease (SD) and 6 (43 %) with PD
(Table 3). After transplantation, 12 patients (85 %) survived.
All five patients receiving transplantation in CR (3 allogeneic,
1 autologous, and 1 haploidentical) were in continuous CR
after 1, 1,7, 8, and 12 months of transplantation, respectively.
None of the patients entering transplantation with SD or PD
(n=9) could achieve remission after transplantation.
Safety/toxicity
In general, the treatment was well tolerated with dose reduc-
tion required in five patients (three due to cytopenias, one
peripheral neuropathy, one unknown). The most common
(>10 %) treatment-related adverse events were fatigue, nau-
sea, neuropathy, neutropenia, vomiting, myalgia, alopecia,
and extremity pain (Table 4).
Neurological toxicity was observed in 20 patients: periph-
eral neuropathy pattern in 17, grade 3–4 neuropathy occurred
in two, and oculomotor nerve palsy in one patient. Two
patients from different centers suffered from generalized tonic
convulsions, one of whom was on renal replacement therapy.
Convulsions occurred after 5 and 2 cycles of BV treatment.
Since drug-induced neurotoxicity could not be excluded, BV
was stopped in both patients.
Discussion
This multicenter, retrospective study was conducted to inves-
tigate activity and safety of BV in patients with cHL. Patients
were managed in a non-trial setting, and the study population
mainly consisted of heavily pretreated, high-risk patients.
Although having multiply relapsed or refractory disease,
ECOG performance status of the patients was ≤2.
In general, treatment was well tolerated, and toxicities were
generally grade 1 and 2 in severity. Patients with organ dys-
function were not excluded. Namely, there were three patients
with chronic kidney disease (one with stage 4 and two with
stage 5, undergoing hemodialysis) included in the study. All
three patients had received previous salvage chemotherapy
Fig 3 Kaplan-Meier plots and 95%CIs for PFS and OS. a Themedian PFS was 7 months. b TheOS at 12months was 70.58%. ThemedianOS has not
yet been reached
Table 4 Most common adverse events reported by >10% of the patients
regardless of relationship with brentuximab vedotin
Adverse event (AE) Total number of patients
with AE, n (%)
Grade 3–4 AE,
n (%)
Fatigue 29 (50.0) –
Nausea 19 (32.8) 2 (3.4)
Neuropathy 18 (31.0) 2 (3.4)
Neutropenia 16 (27.6) 1 (1.7)
Vomiting 15 (25.8) 1 (1.7)
Myalgia 15 (25.8) 2 (3.4)
Alopecia 12 (20.7) –
Extremity pain 12 (20.7) 2 (3.4)
Pyrexia 8 (13.8) –
Muscle spasm 8 (13.8) –
Constipation 7 (12.0) –
Pruritus 7 (12.0) –
Table 3 Disease status
at transplantation N (%)
Complete remission 5 (36)
Stable disease 3 (21)
Progressive disease 6 (43)
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including cisplatin. Two of these patients were treated without
any dose modifications. One of these hemodialysis patients
treated without dose reduction had generalized seizures after
two cycles of BV and therapy was stopped. The other two
patients with stage 4–5 chronic kidney disease did not expe-
rience any particular side effects or deterioration of kidney
function during treatment course.
Interestingly, generalized seizures with a toxicity grade of 3
were reported in two patients from two different centers. One
of the patients had stage 5 chronic kidney disease and seizures
occurred after two cycles as mentioned previously. The other
patient experienced seizures after 5 treatment cycles and treat-
ment was stopped. Grade 3 oculomotor nerve disorder devel-
oped in one patient after 7 BV treatment cycles. Possible
underlying causes were excluded in this patient. One patient
with a previous diagnosis of demyelinating polyneuropathy
did not experience any deterioration of neuropathy during the
treatment course.
The retrospective nature of the analysis of data was a
limitation of the present study.
The finding that patients with less prior chemotherapy
regimens had better CR rates compared with more heavily
pretreated patients (p=0.016) should be interpreted cautiously
because of the low number of less intensively treated patients
and no data in the literature supporting this finding.
Similar to previous studies [6–9], our study also indicates
that best responses to BVare observed after 2–5 cycles, early
during the treatment course. Since best results are obtained
with chemosensitive disease and minimal tumor burden both
in autologous and allogeneic stem cell transplantation, trans-
plantation should be considered earlier during BV treatment
when best responses are achieved.
In the present study, nearly one quarter of patients (n=14)
underwent transplantation (7 allogeneic, 5 haploidentical and
2 autologous) after BV therapy, which is consistent with the
current literature [8,10]. However, only 36 % of these patients
(n=5) were in complete remission before transplantation, and
43 % of patients (n=6) were transplanted with chemoresistant
PD. This poor pre-transplant disease control showed that BV
was not used as an effective bridge to transplant in the present
study. In spite of this fact, 85 % of the transplanted patients
were alive. Consideration of transplantation early during BV
treatment course can improve disease status at transplantation.
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